Immunologic Effect of Fraction of Inspired Oxygen

Sponsor
Assiut University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04772794
Collaborator
(none)
20
1
2
27.6
0.7

Study Details

Study Description

Brief Summary

During anesthesia and surgery, oxygen is routinely administered to all patients. Inspired oxygen concentrations, however, vary between 30% - 100% and oxygen is often administered in a seemingly random manner.

Condition or Disease Intervention/Treatment Phase
  • Other: fraction of inspired oxygen
N/A

Detailed Description

During anesthesia and surgery, oxygen is routinely administered to all patients. Inspired oxygen concentrations, however, vary between 30% - 100% and oxygen is often administered in a seemingly random manner.A striking conundrum is evident immediately when one review studies on the effects of oxygen on cytokines synthesis. Most investigators have found that hyperoxia enhances proinflammtory cytokines transcription and translations (11). In contrast, hyperparic oxygen has generally been shown to suppress stimulus induced porinflammtory cytokine production (12). Other studies have demonstrated that supplemental oxygen improves inflammatory and immune function (13), and it is not associated with clinically important side effect (14). We therefor undertook the current prospective randomized study to investigate whether perioperative supplemental oxygen (30% versus 80%) on pro and anti-inflammatory response in patients undergoing major abdominal cancer surgeries as our primary outcome.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Immunological Effect of Intraoperative Fraction of Inspired Oxygen in Patients Undergoing Major Abdominal Cancer Surgery
Actual Study Start Date :
Jan 13, 2020
Anticipated Primary Completion Date :
Jan 1, 2022
Anticipated Study Completion Date :
May 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: hyperoxygenation group

Intraoperative administration of a mixture of 80% oxygen and 20% air

Other: fraction of inspired oxygen
after induction of general anaesthesia, different fraction of inspired oxygen will be given to patient according to their group allocation

Placebo Comparator: control group

intraoperative administration of 30% oxygen and 70% air

Other: fraction of inspired oxygen
after induction of general anaesthesia, different fraction of inspired oxygen will be given to patient according to their group allocation

Outcome Measures

Primary Outcome Measures

  1. changes in serum level of interlukin 6 [before operation (0), 1st, 3rd, and 7th days postoperative]

    serum level of interlukin 6 will be measured by ELISA technique

  2. changes in serum level of interlukin 10 [before operation (0), 1st, 3rd, and 7th days postoperative]

    serum level of interlukin 6 will be measured by ELISA technique

Secondary Outcome Measures

  1. changes in total WBCs count [before operation (0), 1st, 3rd, and 7th days postoperative]

    measurement of total white blood cells count

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • candidates for abdominal cancer surgeries
Exclusion Criteria:
  • Patients with chronic diseases, such as chronic obstructive pulmonary disease or pneumonia,

  • body mass index (BMI) >35 kg/m2,

  • severe malnutrition (albumin <3),

  • leukopenia (white blood cell <4,000 g/dL),

  • surgery within the previous 30 days and

  • O2 saturation < 90%, as measured using a pulse oximeter

Contacts and Locations

Locations

Site City State Country Postal Code
1 Assiut University Assiut Egypt 171516

Sponsors and Collaborators

  • Assiut University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Shereen Mamdouh, Associate Professor, Assiut University
ClinicalTrials.gov Identifier:
NCT04772794
Other Study ID Numbers:
  • 519
First Posted:
Feb 26, 2021
Last Update Posted:
Feb 26, 2021
Last Verified:
Feb 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Shereen Mamdouh, Associate Professor, Assiut University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 26, 2021